Cisplatin-induced acute renal failure is ameliorated by erdosteine in a dose-dependent manner.
The aim of this study was to investigate the optimum dosage of erdosteine to ameliorate cisplatin-induced nephrotoxicity. Three different doses of erdosteine at 25, 50 and 75 mg kg(-1) were studied in rats. Intraperitoneal administration of 7 mg kg(-1) cisplatin led to acute renal failure, as indicated by kidney histology and increases in plasma creatinine and blood urea nitrogen (BUN) levels. At 5 days after cisplatin injection the BUN level was increased significantly from 15.1 +/- 4.3 to 126.7 +/- 152.6 mg dl(-1) and plasma creatinine levels increased from 0.37 +/- 0.005 to 1.68 +/- 1.9 mg dl(-1). When the rats were administered 50 and 75 mg kg(-1) erdosteine 24 h before cisplatin injection that was continued until sacrifice (total of 6 days), the BUN and creatinine levels remained similar to control levels and the grade of histology was similar. Erdosteine at doses of 50 and 75 mg kg(-1) ameliorates cisplatin-induced renal failure. The optimum dose of erdosteine may be 50 mg kg(-1) in this study.
Ozyurt
Hüseyin
H
Gaziosmanpasa University School of Medicine, Department of Biochemistry, Tokat, Turkey.
Yildirim
Zeki
Z
Kotuk
Mahir
M
Yilmaz
H Ramazan
HR
Yağmurca
Murat
M
Iraz
Mustafa
M
Söğüt
Sad
S
Gergerlioglu
Serdar
S
D058186:Acute Kidney Injury / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D000284:Administration, Oral; D000818:Animals; D001806:Blood Urea Nitrogen; D002945:Cisplatin / Q000633:toxicity*; D003404:Creatinine / Q000097:blood; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D016166:Free Radical Scavengers / Q000008:administration & dosage / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D013864:Thioglycolates / Q000008:administration & dosage / Q000627:therapeutic use*; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use*
D016166:Free Radical Scavengers; D013864:Thioglycolates; D013876:Thiophenes; C048498:erdosteine; D003404:Creatinine; D002945:Cisplatin